Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
The BPaLM regimen, which consists four-drug combination – Bedaquiline, Pretomanid, Linezolid and Moxifloxacin, has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure
Coal India has committed to providing upto Rs. 3 crore to treat thalassaemia and aplastic anaemia patients for a period of 3 years
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
The conference aims to bring various stakeholders and experts in the field of healthcare and digital solutions for ensuring ‘universal access to affordable and quality healthcare’
Transform healthcare by integrating expertise from AI, clinical sciences, and basic sciences to harness India’s extensive data sets for improving the access to healthcare
Effective, holistic, science-backed targeted solutions for symptomatic treatment
Subscribe To Our Newsletter & Stay Updated
